Showing 201 - 220 results of 346 for search '"ovarian cancer"', query time: 0.08s Refine Results
  1. 201
  2. 202

    Humoral Autoimmune Responses to Insulin-Like Growth Factor II mRNA-Binding Proteins IMP1 and p62/IMP2 in Ovarian Cancer by Xinxin Liu, Hua Ye, Liuxia Li, Wenjie Li, Yi Zhang, Jian-Ying Zhang

    Published 2014-01-01
    “…Ovarian cancer is one of the leading causes of cancer-related deaths among women. …”
    Get full text
    Article
  3. 203

    Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines by Simon J. Hogg, Kenny Chitcholtan, Wafaa Hassan, Peter H. Sykes, Ashley Garrill

    Published 2015-01-01
    “…This study demonstrates that resveratrol and its derivatives may inhibit growth of 3D cell aggregates of ovarian cancer cell lines via different signalling molecules. …”
    Get full text
    Article
  4. 204
  5. 205

    LncRNA FAM225B Regulates PDIA4-Mediated Ovarian Cancer Cell Invasion and Migration via Modulating Transcription Factor DDX17 by Chanjiao Yao, Lingjuan Zeng, Qin Liu, Xiaoxin Qiu, Chunyan Chen

    Published 2023-01-01
    “…This study aimed to explore the roles and mechanisms of lncRNA FAM225B and PDIA4 in ovarian cancer. Methods. RT-qPCR and Western blot assays were performed to detect the expression levels of the lncRNAs FAM225B, DDX17, and PDIA4 in the serum of patients with ovarian cancer and cell lines. …”
    Get full text
    Article
  6. 206
  7. 207

    Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway by Attalla Farag El-kott, Ali A. Shati, Mohammed Ali Al-kahtani, Sultan Alqahtani

    Published 2019-01-01
    “…Human A2780 ovarian cancer cells were cultured with or without AG treatment in the presence or absence of cisplatin. …”
    Get full text
    Article
  8. 208
  9. 209
  10. 210
  11. 211
  12. 212
  13. 213
  14. 214
  15. 215

    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer by Lini Pandite, Simon Metenou, Debra L Richardson, Erika Hamilton, Linda Van Le, Bo Ma, Fatima Rangwala, Nehal J Lakhani, Justin Call, Daphne Stewart, Lauren E Dockery, Guanfang Wang, Jade Huguet, Elliot Offman

    Published 2025-01-01
    “…A first-in-human phase I trial of SL-172154 was conducted in patients with platinum-resistant ovarian cancer.Methods SL-172154 was administered intravenously at 0.1, 0.3, 1.0, 3.0, and 10.0 mg/kg. …”
    Get full text
    Article
  16. 216
  17. 217
  18. 218
  19. 219
  20. 220